

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Peijia Medical Limited

沛嘉醫療有限公司

(Incorporated in the Cayman Islands with limited liability)

(Stock Code: 9996)

VOLUNTARY ANNOUNCEMENT

First Patient Implant in Clinical Trial of TaurusNXT®

This announcement is made by Peijia Medical Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to provide the shareholders of the Company and potential investors with updated information in relation to the latest business and new product development progress of the Group.

The board (the “**Board**”) of directors (the “**Directors**”) of the Company is pleased to announce that the Company has recruited the first patient of the multi-center clinical trial for TaurusNXT®, the Company’s third-generation transcatheter aortic valve replacement (“**TAVR**”) system, and the first implant is successfully completed by Zhongshan Hospital of Fudan University.

TaurusNXT® is the Company’s latest clinical stage TAVR system that includes the Company’s patented and in-house developed anti-calcification technologies such as non-glutaraldehyde pericardium treatment and dry-tissue technology. The company believes that the application of the anti-calcification technologies on TAVR can significantly enhance the durability and biocompatibility of the prosthetic aortic valve, without sacrificing other key performance metrics.

The clinical trial of TaurusNXT® is a multi-center, prospective, single-arm objective performance criteria study of assessing the safety and efficacy of TaurusNXT® TAVR system for treating patients with severe aortic stenosis. The study is led by Professor Ge Junbo from Zhongshan Hospital of Fudan University, and involves more than 15 top centers across China.

THE COMPANY MAY NOT BE ABLE TO ULTIMATELY DEVELOP AND MARKET TaurusNXT® SUCCESSFULLY. SHAREHOLDERS OF THE COMPANY AND POTENTIAL INVESTORS ARE ADVISED TO EXERCISE DUE CARE WHEN DEALING IN THE SHARES OF THE COMPANY.

By order of the Board
Peijia Medical Limited
Dr. Yi Zhang
Chairman and Executive Director

Hong Kong, September 13, 2021

As of the date of this announcement, the Board comprises Dr. Yi Zhang, Mrs. Ping Ye Zhang and Ms. Hong Ye as executive Directors, Dr. Zhiyun Yu, Mr. Jifeng Guan, Mr. Fei Chen, Mr. Jun Yang as non-executive Directors, and Dr. Stephen Newman Oesterle, Mr. Robert Ralph Parks, and Mr. Wai Ming Yip as independent non-executive Directors.